Express Pharma
Home  »  Research  »  Merck KGaA signs deal with Artios Pharma for cancer drugs research

Merck KGaA signs deal with Artios Pharma for cancer drugs research

Artios will receive $30 million in up-front and near-term payments, plus double-digit option fees and up $860 million total milestones per target

0 125
Read Article

Germany’s Merck KGaA has signed a three-year strategic research deal with Artios Pharma to discover and develop up to eight potential targeted treatments for cancer.

Under the agreement, Artios will receive $30 million in up-front and near-term payments, plus double-digit option fees and up to $860 million total milestones per target.

Merck said in a statement it will have the right to opt into exclusive development and commercialisation of compounds on up to eight targets.

(Edits by EP News Bureau)

Leave A Reply

Your email address will not be published.

 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image
Know Importance of using different levels of Controls
Register Now!
close-image